By default, metachronous bladder recurrences after UTUC surgery have been managed similarly to primary non-muscle invasive bladder cancer.

DEAR DR. ROACH: When I was about 6 years old in the early 1940s, my 16-year-old brother was sent to a sanitarium for tuberculosis patients. He was there for 18 months and was a survivor. During this ...

The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the treatment of bladder cancer. The PD-1/antibody-drug conjugate pairing ...

Radiation therapy (RT) for muscle-invasive bladder cancer (MIBC) requires substantial planning target volume (PTV) margins to accommodate bladder-filling variability. We hypothesized that cone beam ...

The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, as a perioperative neoadjuvant treatment and postcystectomy ...

Novel immunotherapy combinations, like durvalumab with neoadjuvant chemotherapy, significantly improve event-free and overall survival in MIBC. Pembrolizumab plus enfortumab vedotin has shown efficacy ...

A "first-in-class" intravesical gemcitabine (Gemzar)-releasing system holds promise as a novel bladder-sparing treatment for patients with advanced/refractory solid Bacillus Calmette-Guérin ...

Doctors Are Sounding the Alarm on Overused CT Scans :warning: A new study from Yale reveals a troubling trend — the use of head CT scans has doubled since 2007, and it could be silently driving up ...

The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...

What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...